Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

• Hauptverfasser: Thomas J. Esparza (Verfasst von), Yaozong Chen (Verfasst von), Negin P. Martin (Verfasst von), Helle Bielefeldt-Ohmann (Verfasst von), Richard A. Bowen (Verfasst von), William D. Tolbert (Verfasst von), Marzena Pazgier (Verfasst von), David L. Brody (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

There remains an unmet need for globally deployable, low-cost therapeutics for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previously, we reported on the isolation and in vitro characterization of a potent single-domain nanobody, NIH-CoVnb-112, specific for the...